Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

Key Points

• To assess the effectiveness of annual PSA screening in detecting clinically relevant prostate cancer in BRCA1 and BRCA2 pathogenic variant carriers.
• Conducted annual PSA screening for BRCA1 and BRCA2 PGV carriers.
• Compared findings to noncarriers to evaluate differences in detection rates.
• Analyzed incidence of clinically significant prostate cancer (csPC) and NCCN risk categories.
• BRCA2 PGV carriers showed a higher incidence of csPC compared to noncarriers.
• PSA screening in BRCA1 PGV carriers also detected early NCCN intermediate/high-risk prostate cancer.
• Findings support systematic PSA screening for BRCA2 PGV carriers and suggested consideration for BRCA1 PGV carriers.